Selected novel aspects in pathogenesis of lupus erythematosus – interdisciplinary view

Kalińska-Bienias, Agnieszka; Foroncewicz, Bartosz; Bienias, Piotr; Kowaléwski, Cezary

doi:10.5114/dr.2016.62884

Cited by 1 publication

(1 citation statement)

References 57 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It seems that they could contribute to a fuller understanding of lupus erythematosus pathogenesis. Available scientific reports indicate an increased serum level of Gal-3 in patients with SLE [ 9 – 11 , 14 , 18 ]. As regards G3BP, a particularly promising assessment was presented by the Nielsen et al .…”

Section: Discussionmentioning

confidence: 99%

Serum galectin-3 and galectin-3 binding protein levels in systemic lupus erythematosus and cutaneous lupus erythematosus

Kalińska-Bienias

Kowalczyk

Bienias

et al. 2020

pdia

Self Cite

View full text Add to dashboard Cite

Introduction: The roles of galectin-3 (Gal-3) and galectin-3 binding protein (G3BP) in systemic lupus erythematosus (SLE) are of ongoing interest, but the data are insufficient due to highly limited available studies. There are no data on cutaneous lupus erythematosus (CLE). Aim: To assess serum Gal-3 and G3BP concentrations in SLE patients with and without LE-specific skin lesions, CLE patients and to correlate levels of proteins with clinical and laboratory parameters. Material and methods: The study included 71 SLE patients with and without LE-specific skin lesions, 23 CLE patients and 40 controls. Gal-3 and G3BP were measured by specific enzyme-linked immunosorbent assays (ELISA). Results: Serum Gal-3 and G3BP concentrations were significantly higher in SLE with and without LE-specific lesions compared to controls, but without differences between SLE groups. Gal-3 and G3BP levels were also elevated in CLE compared to controls (p = 0.001, p = 0.005; respectively). There was a positive correlation between G3BP level and CLASI activity score both in CLE (r = 0.55, p = 0.006) and in SLE patients with LE-specific lesions (r = 0.36, p = 0.02). G3BP and Gal-3 levels did not differ in SLE with LE-specific lesions and CLE. There was a positive correlation between serum G3BP level and the SLEDAI score in SLE patients (r = 0.26, p = 0.03). Conclusions: Our findings indicate that serum G3BP and Gal-3 are elevated in CLE. Additionally, G3BP might be associated with the extent of skin lesions. There are no differences between G3BP and Gal-3 concentrations in SLE with and without LE-specific skin lesions.

show abstract